Get the Stockscreener App
10.12
4.12%
0.40
After Hours:
10.12
Olema Pharmaceuticals Inc stock is traded at $10.12, with a volume of 376.35K.
It is up +4.12% in the last 24 hours and down -12.38% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$9.72
Open:
$9.84
24h Volume:
376.35K
Relative Volume:
0.79
Market Cap:
$586.16M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-4.1992
EPS:
-2.41
Net Cash Flow:
$-83.73M
1W Performance:
+22.22%
1M Performance:
-12.38%
6M Performance:
+11.70%
1Y Performance:
-23.28%
1-Day Range:
$9.6201
$10.42
1-Week Range:
$7.675
$10.42
52-Week Range:
$7.675
$16.77
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
10.12 | 586.16M | 0 | -96.66M | -83.73M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Great Point Partners LLC Buys 203,120 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals stock upgraded on strong trial data By Investing.com - Investing.com Canada
Olema Oncology to Present New Breast Cancer Treatment Data at SABCS 2024 | OLMA Stock News - StockTitan
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up – Still a Buy? - Defense World
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap UpHere's Why - MarketBeat
Victory Capital Management Inc. Has $10.17 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals stock hits 52-week low at $8.51 - Investing.com
Olema Pharmaceuticals stock hits 52-week low at $8.51 By Investing.com - Investing.com UK
What is Lifesci Capital’s Estimate for OLMA FY2025 Earnings? - Defense World
Equities Analysts Issue Forecasts for OLMA FY2024 Earnings - Defense World
What is Lifesci Capital's Forecast for OLMA FY2025 Earnings? - MarketBeat
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
OLMAOlema Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Oncology to Present at Three Major Healthcare Investor Conferences | OLMA Stock News - StockTitan
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) PT at $27.00 - MarketBeat
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation - Yahoo Finance
Possible Bearish Signals With Olema Pharmaceuticals Insiders Disposing Stock - Simply Wall St
SG Americas Securities LLC Acquires Shares of 13,056 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals (NASDAQ:OLMA) Earns Buy Rating from HC Wainwright - MarketBeat
Olema Pharmaceuticals maintains Buy rating from H.C. Wainwright By Investing.com - Investing.com UK
Olema stock a buy as Goldman highlights promising preclinical data for KAT6 inhibitor - Investing.com UK
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 - The Manila Times
Insider Selling: Paradigm Biocapital Advisors L, Olema Pharmaceuticals Inc [OLMA] 10% Owner divested 2,400,000 shares – Knox Daily - Knox Daily
Closing Bell Recap: Olema Pharmaceuticals Inc (OLMA) Ends at 11.26, Reflecting a -1.23 Downturn - The Dwinnex
Can you still get a good price for Olema Pharmaceuticals Inc (OLMA) Shares at this point? - US Post News
Renaissance Technologies LLC Buys Shares of 53,200 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times
Point72 Asset Management L.P. Purchases New Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Aurigene Oncology, Olema Pharmaceuticals identify KAT6A inhibitors - BioWorld Online
Brokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Target Price at $27.00 - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by Dimensional Fund Advisors LP - Defense World
OLMA Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
OLMA underperforms with a -4.07 decrease in share price - US Post News
74,657 Shares in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Acquired by Dana Investment Advisors Inc. - MarketBeat
olema pharmaceuticals, inc. Earnings dates - RTTNews
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.8% - MarketBeat
Keeping an Eye on Olema Pharmaceuticals Inc (OLMA) After Insider Trading Activity - Knox Daily
Insider’s View: Deciphering Olema Pharmaceuticals Inc (OLMA)’s Financial Health Through Ratios - The Dwinnex
Long Term Trading Analysis for (OLMA) - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Purchased by Marshall Wace LLP - Defense World
Ensign Peak Advisors Inc Acquires 850 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Purchases Shares of 275,000 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Affinity Asset Advisors LLC Invests $2.98 Million in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Rhumbline Advisers Buys 17,953 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):